Algorhythm Holdings, Inc.: Algorhythm Holdings Reports Second Quarter 2026 Financial Results

Algorhythm Holdings (NASDAQ: RIME) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue rose to $3.0 million, up 25% sequentially and 161% year over year. Gross margin improved about 850 bps sequentially. Cash and restricted cash totaled about $8.0 million, and total assets increased to $18.6 million.

Original reporting
Published Aug 14, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 2:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RIME
Bullish
medium confidence
Mentioned
$RIME
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$RIMEBullishMed
01

Why it matters

Traders can update expectations for near-term growth and gross margin trajectory based on the reported sequential and YoY revenue increases and the 850 bps gross margin improvement, alongside new/expanded customer agreements.

02

Market read

This is a company-specific earnings release with quantified growth and margin improvement plus contract wins, which can drive immediate repricing versus prior expectations.

03

What to watch

The excerpt shows gross loss and operating expense lines but does not provide net income, cash burn, or full segment economics, limiting confidence in sustainability of margin gains.

Relevance 8/10Novelty 7/10Timing: today’s Q2 2026 results release

Background

Algorhythm Holdings, Inc. (NASDAQ: RIME) released its second quarter 2026 financial results and highlighted SemiCab customer and platform expansion.

Company-level read

Ticker impact

$RIMEBullishMedium confidence
Context

Algorhythm Holdings reported Q2 2026 revenue of $3.0M, up 25% sequentially and 161% YoY, plus gross margin expansion and cash balance.

Expected impact

Moderately positive bias for the stock on earnings-day sentiment, with follow-through dependent on whether margin gains are sustainable.

Evidence & confidence

The release provides multiple quantified operating metrics (revenue growth, gross margin +850 bps, cash $8.0M) and specific customer contract expansions, but it is still a small-cap with limited detail on operating income and forward guidance in the excerpt.

Market effects

AI logistics and supply-chain software names may see sentiment lift if investors view SemiCab’s customer wins and margin expansion as proof of demand.

No clear regional read-through beyond US small-cap tech sentiment.

Customer expansion references India and North America, but the excerpt lacks broader international guidance.

Counterpoint

Revenue growth and gross margin improvement may be driven by timing or mix, while the balance sheet shows sizable liabilities and accumulated deficit that could pressure future dilution or financing needs.

Key entities

  • Algorhythm Holdings, Inc.

    AI-powered logistics solutions provider and owner/operator of SemiCab; reported Q2 2026 results and business updates.

  • SemiCab

    AI-enabled collaborative transportation platform referenced in revenue and customer expansion highlights.

  • Procter & Gamble India

    Relationship expanded via an additional contract expansion, increasing annualized contract value by about 32%.

  • Onida Electronics

    Signed a new Master Services Agreement expanding SemiCab’s enterprise customer portfolio in India.

Related articles

$RIMEMed

Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75

Carets Corp is exploring a potential sale, including its technology and patents. Algorhythm Holdings (RIME) and Biomerica (BMRA) are evaluating strategic alternatives. nVent Electric (NVT) acquired Maverick Power for $1.75B, with up to $550M more in performance-based payments. Descartes (DSGX) bought Tai for $100M, and Navitas (NVTS) acquired Claros for up to $232.8M. Booz Allen (BAH) completed a $720M acquisition, and Elastic (ESTC) acquired Deductive AI. BioXcel (BTAI) filed for Chapter 11 ban

$IPHAMed

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.

$UPXIMed

Upexi Inc (UPXI) (Q4 2026) Earnings Call Highlights: Massive Solana Treasury Fuels $246

Upexi Inc. (UPXI) reported Q4 2026 earnings, highlighting a $246M net loss driven by digital asset losses. CEO Alan Marshall discussed Solana treasury management, debt restructuring, and cost-cutting efforts. The company holds 2.34M Solana tokens, with staking revenue covering expenses. Management emphasized creative capital allocation and potential expansion in Asian markets through the Hivemind partnership. Stockholders' equity was negative $53.8M as of June 30, 2026.

$RBAMedAI 8/10

RB Global’s (RBA) Earnings Jump While Its Take Rate Shrinks

RB Global (RBA) reported Q2 earnings with net income up 33% YoY to $132M, EPS up 34% to $0.71, and revenue up 11% to $1.3B. Automotive segment drove GTV growth of 13%. Acquisitions boosted growth, but organic GTV growth was 7%. Service revenue take rate fell 110 bps to 20.0%. Management raised full-year guidance and increased the dividend. Hedge fund ownership declined, and short interest is high at 10.54% of float.

$CRBGMed

A GAAP Loss Masks What Corebridge (CRBG) Actually Earned This Quarter

Corebridge Financial (CRBG) reported a GAAP net loss of $16M for Q2, but adjusted operating income was $512M. Institutional Markets saw strong growth, while Individual Retirement segment declined. The company returned $412M to shareholders and approved a merger with Equitable Holdings. Adjusted pre-tax income fell 21%, and total premiums dropped 13%.

$JHXMedAI 8/10

James Hardie (JHX) Crushes Guidance and Raises Its Full-Year Outlook

James Hardie (JHX) reported Q1 FY2027 results with net sales up 64% YoY to $1.475B, adjusted EBITDA up 79% to $422.1M, and raised full-year guidance. The company cited strong execution, cost synergies from the AZEK acquisition, and share gains in its core business. CEO Aaron Erter noted the beat was not due to housing market improvement. Free cash flow doubled to $254.2M, used to pay down debt. Shares trade at a forward P/E of 21.79.